Takeda continues post-Shire selloff, inching closer to $10B goal

The Takeda selloff continues.

In the latest of the Japanese pharma’s post-merger trimmings, Takeda has sold off a portfolio of “non-core” over-the-counter and prescription products marketed exclusively in Asia to the South Korean-based Celltrion. The departing portfolio generated $140 million in net 2018 sales. Takeda will receive $266 million, with another $12 million available in milestones.